The Swiss pharma giant said it intends to hold on to Alcon’s $4.6 billion ophthalmic pharmaceuticals business under the Novartis Innovative Medicines umbrella, continuing a transition begun in January 2016. If consummated as expected during the first half of 2019, the separation of the remaining the surgical and vision care business would create a $7 billion enterprise with more than 20,000 employees, Novartis said.
IN CASE YOU MISSED IT
- BD to shutter Minnesota Lutonix plant, layoffs ahead for 53
- Frequency Therapeutics launches hearing loss trial, gains the fast track at FDA
- OcuMedic, Gelest ink drug-delivering contact lens deal
- BioCardia wins CE Mark renewal for Helix, Morph catheters
- Walmart brings One Drop wireless glucose meter kit to stores